Referent:innen

Dr. Michael Ruffing

Dr. Michael Ruffing

Boehringer Ingelheim Pharma

Dr. Johannes Blümel

Dr. Johannes Blümel

Paul-Ehrlich-Institut

Dr. Albrecht Gröner

Dr. Albrecht Gröner

PathoGuard Consult

Michael Schiffer

Michael Schiffer

CSL Behring

Zielsetzung

The course aims to explain the complex nature of viruses that move between the concepts of life and death. It provides participants with a fundamental understanding of viral and pathogen safety in the pharmaceutical industry. Participants will acquire basic knowledge of virology, including the physiology of viruses, their replication cycles, transmission routes and resistance mechanisms. This knowledge is essential for risk assessment and the development of safety strategies.

In addition, the programme teaches advanced safety strategies for dealing with viruses and testing methods, including NGS (next generation sequencing) and other modern diagnostic methods. Participants will learn best practices for viral inactivation and validation to ensure products meet industry requirements and global regulatory frameworks such as ICH Q5A, the European Medicines Agency (EMA) and the European Pharmacopoeia.

The course also provides practical insights into the control of viral contamination, including risk mitigation strategies through facility segregation, risk analysis and contamination risk management. Finally, advanced virus detection methods, including NGS, and safety-related aspects of Advanced Therapy Medicinal Products (ATMP), such as gene and cell-based therapies, will be highlighted.

Hintergrund

The past has shown us that the development and production of vaccines can also attract enormous public attention. This makes it all the more important, especially when it comes to approval and production under time pressure, that the quality standards of good manufacturing practice are observed.

Virus safety is one of the major concerns in the development and production of biopharmaceuticals and biologics. Huge efforts are undertaken to prevent viral contamination. A series of guidelines was dedicated to that topic exclusively.

For many people who are involved in the development and production of biopharmaceuticals and biologics the world of viruses is a “black box”.

Zielgruppe

This Education Course is directed to responsible personnel involved in the development and production of biopharmaceuticals and biologics
  • Research & Development
  • Quality Assurance
  • Regulatory Affairs
  • Production
  • Engineering
  • Quality Control
It is also useful for service providers, such as contract research organisations and contract manufacturers.

Presentations / Certificate

The presentations for this event will be available for you to download and print before and after the event. Please note that no printed materials will be handed out on site and that there will not be any opportunity to print the presentations on site.

After the event, you will automatically receive your certificate of participation.

Programm

Virus Safety - Best Practices and Emerging Trends

Gesamtes Programm als PDF herunterladen

Elemental (basic) Virology
  • Physiology (if you can use such a word)
  • Replication cycles
  • Vectors
  • Resistance properties
Virus Safety Strategy: Approaches and Test Procedures
  • Viral safety approach: Regulations and principles
  • Virus testing concept
  • Methods for detection of exogenous & endogenous virus
Virus Management: Methods for Inactivation and Validation Studies in Adventitious Virus Management
  • Virus contamination of starting material for biologicals
  • Dedicated virus reduction steps vs. manufacturing steps for protein purification and concentration
  • Down scaling of manufacturing steps for virus clearance studies
  • Virus clearance studies
    • Virus spike preparation
    • Controls as cytotoxicity / interference / balance /inctivation kinetic
    • Virus detection methods – infectivity vs. NAT
    • Robustness of virus reduction methods / DoE studies
Virus Safety: Regulatory Background
  • ICH Guidelines (ICH Q5A)
  • European Guidelines (EMEA)
  • European Pharmacopoeia
  • Risk assessment
  • Clinical trials in Europe
Virus Contamination Control in pharmaceutical Production
  • Adventitious agents contamination control strategies
  • Facility segregation & risk Analysis
  • Methods of risk assessment and minimization
  • Case studies
Pathogen Safety Risk Management
  • Strategies for ensuring product quality and safety
  • What to consider and how to perform risk assessments regarding pathogen safety
  • Deviations and change management
  • Case studies
Next Generation Sequencing (NGS) - a powerful Technology for Virus Detection
  • Technology & applications
  • Regulations, e.g., in ICH Q5A & Ph. Eur.
Virus-based Advanced Therapy Medicinal Products (ATMPs)
  • Applications
  • Oncolytic viruses: Mode of action & adventitious virus safety approach
  • AAV - efficient gene therapy vector
    • Production of AAV for gene therapy
    • Quality Control of AAV
    • Clinical applications of AAV
Virus Safety Aspects of Advanced Therapy Medicinal Products (ATMP)
  • Regulatory background/certification
  • Gene therapy medicinal products
  • Cell based medicinal products
Transmissible Spongiform Encephalopathy (TSE) – Biology & Regulatory
  • Nature and transmission of TSE Agent
  • TSE agent detection Methods
  • Prion reduction Methods
  • EU legislation / EMA note for guidance / reflection paper
  • EDQM TSE Certification

ECA-Member*: € 1890,-
Non ECA Member*: € 2090,-
EU/GMP Inspectorates*: € 1045,-
APIC Member Discount*: € 1990,-

Alle Preise zzgl. MwSt. Wichtige Hinweise zur Umsatzsteuer.

* auch unkompliziert per Kreditkarte bezahlbar
American Express Visa Mastercard

icon
Weitere Termine vor Ort
Weitere Termine vor Ort nicht verfügbar
icon
Weitere Termine online
Weitere Termine online nicht verfügbar
icon
Aufzeichnung nicht verfügbar

Zurück

Teilnehmerstimmen - das sagen andere über unsere Seminare:

"Die Umsetzung mit Memberspot ist wirklich ausgezeichnet gelungen.
Es unterstützt die Wissensvermittlung und gewährleistet auch die richtige Durchführung des Kurses.”
Christian Wagener, WAGENER & CO. GmbH
GMP Basis-Einstiegsschulung (B 1) - Aufzeichnung Online Seminar, April 2024

„Kurzweilig, informativ“
Behrendt, Christian, IOI Oleo GmbH


„Austausch zwischen Teilnehmern & Vortragenden sorgt für Anstöße & Optimierungsmöglichkeiten im eigenen Unternehmen! Praxisnahe Beispiele veranschaulichen und vertiefen die Theorie sehr gut“
Marina Maier, CHEPLAPHARM Arzneimittel GmbH

Abweichungen und CAPA (QS 12)
November 2024

„Danke für das tolle und interessante Seminar! Ich nehme mir fachlich total viel mit und habe viele tolle Menschen kennengelernt.“
Melanie Schifferer, DAIICHI SANKYO EUROPE GmbH
Batch Record Review (QS 23)
September 2024

Guter, breit gefächerter Überblick mit interessanten Verknüpfungen zur Praxis,
welche die Theorie super veranschaulicht.”
Marina Kicoranovic, Labor Hartmann GmbH
GMP/Basis-Einstiegsschulung (B 14), September 2023

Die Referenten waren sehr gut! Sie haben sehr klar gesprochen, nur sehr wenige englische Begriffe
verwendet (super) und waren sehr praxisbezogen.”
Astrid Gießler, Regierungspräsidium Karlsruhe
Live Online Seminar - Basiskurs Computervalidierung & Datenintegrität im GxP Umfeld (B 3), Juni 2023

Sehr guter Bezug zur Schulung für einen GMP-Anfänger. Habe mich sehr gut abgeholt gefühlt.”
Dr. Harald Werner, Infraserv GmbH & Co. Höchst KG
GMP-Basisschulung (B 1), Juni 2023

„Interessante Themen, gut vorgetragen, die eigenen Erfahrungen der Vortragenden helfen, dies noch besser nachzuvollziehen.“ „Gute Gestaltung der Workshops, das Zusammenarbeiten in Gruppen und der Austausch mit anderen hilft sehr.“
Manuela Seibert, Merck, GMP-Leadauditor/in (FA 2), April 2024

NEWSLETTER

Bleiben Sie informiert mit dem GMP Newsletter von Concept Heidelberg!

GMP Newsletter

Concept Heidelberg bietet verschieden GMP Newsletter die Sie auf Ihren Bedarf hin zusammenstellen können.

Hier können Sie sich kostenfrei registrieren.

Kontakt

Kontaktieren Sie uns

Haben Sie Fragen?

Concept Heidelberg GmbH
Rischerstraße 8
69123 Heidelberg

Tel. :+49622184440
Fax : +49 6221 84 44 84
E-Mail: info@concept-heidelberg.de

zum Kontaktformular